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The BET bromodomain proteins, such as BRD3 and BRD4, bind to acetylated lysine residues on histone proteins as chromatin readers, and play essential roles in the transcription of oncogenes such as C-MYC, MYCN, BCL2 and FOSL1 (3) (4) (5) (6) (7) (8) . Small molecule BET bromodomain inhibitors, such as JQ1 and I-BET151, competitively bind to acetyl-lysine recognition pockets, displace BET bromodomain proteins from chromatin, and reduce the expression of oncogenes, leading to cancer cell growth inhibition and apoptosis. BET bromodomain inhibitors have shown promising in vitro and in vivo anticancer effects against NUT-midline carcinoma, multiple myeloma, lymphoma, leukemia, medulloblastoma and neuroblastoma (3) (4) (5) (6) (7) (8) (9) (10) . However, treatment with BET bromodomain inhibitors alone does not cause cancer remission in neuroblastoma-bearing mice.
Histone deacetylases (HDACs) remove the acetyl group from the lysine residue on histone tails, leading to chromatin compaction and transcriptional repression, mainly of tumor suppressor genes (11) . HDAC inhibitors, such as panobinostat, induce cancer cell growth inhibition, differentiation and apoptosis in vitro and suppress tumour progression in mice 5 than a dozen HDAC inhibitors (such as vorinostat and panobinostat) currently being evaluated in the clinic and/or clinical trials (11) .
In this study, we investigated the therapeutic efficacy of combination therapy with the BET bromodomain inhibitor JQ1 and the HDAC inhibitor panobinostat against neuroblastoma. JQ1 and panobinostat synergistically reduced the transcription of the LIN28B oncogene, leading to synergistic post-transcriptional reduction in N-Myc oncoprotein expression, and exerted synergistic anticancer effects in vitro and in vivo. 
Small interfering RNA (siRNA) and plasmid transfection
Cells were transfected with 20 nM siRNAs using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) or transfected with 50 ng plasmid using Lipofectamine 2000 reagent, 100 µl opti-Minimum Essential Medium and 900 µl serum-free medium as we have described previously (18, 19) . Validated control siRNA and siRNAs specifically targeting NMyc, BRD3, BRD4, BRD2 or LIN28B were purchased from Qiagen, Hamburg, Germany.
Quantitative real-time RT-PCR
RNA was extracted from cells using PureLink RNA Mini kit (Invitrogen). After cDNA synthesis, real-time RT-PCR was performed as we have described (18, 19 
Alamar blue assays
Cells were incubated with Alamar blue, and read on a microplate reader at 570/595 nm. Results were calculated according to optical density absorbance units, and expressed as percentage change in the number of cells relative to controls (18, 19) .
Flow cytometry studies
Cells were harvested, washed and then stained with FITC-conjugated Annexin V and 7-AAD (BD Biosciences, San Jose, CA). Detection of the cells positively stained with Annexin V and/or 7-AAD were performed using a FACS Canto Flow Cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar Inc, Ashland, OR).
Chromatin immunoprecipitation (ChIP) assays
Research. ChIP assays were performed with an anti-BRD3, anti-BRD4 or control antibody, and PCR carried out with primers targeting a negative control or the intron 1 region of the LIN28B gene promoter (15) .
Luciferase reporter assays
A LIN28B gene promoter construct was kindly provided by Dr. Joshua T. Mendell (15) . Kelly neuroblastoma cells were transfected with control siRNA, BRD3 siRNA-1 or BRD4 siRNA-2, followed by co-transfection with Cypridina TK control construct plus the pGL3 construct expressing empty vector or the LIN28B gene promoter (-1414bp to + 1403bp) for 48 hours. Luciferase activity was measured, and expressed as percentage change relative to control siRNA transfected samples as we have described previously (19) .
Differential gene expression study
SK-N-BE(2) cells were treated with control solvent, JQ1 (1 µM) (prepared in house by the Bradner Lab, Dana-Farber Cancer Institute), panobinostat (10 nM) (Selleckchem, Houston, TX), or JQ1 plus panobinostat. RNA was harvested at 6 hours after treatment, and subjected to Affymetrix microarray (Santa Clara, CA) analysis of differential gene expression. Gene expression was normalized with global normalization, the LimmaGP module (Gene Pattern, Broad Institute, Cambridge, MA) was used to identify genes differentially expressed between samples, and LimmaGP generated .rnk files were used for gene set enrichment analysis (GSEA). An enrichment score (ES) was calculated for each gene set, and enrichment plots were generated for each gene set. Gene expression data is available from Gene Expression Omnibus Expression (GEO) (accession number GSE68690).
Experimental therapy in neuroblastoma-bearing mice
Research. 
Immunohistochemistry analysis
Mouse tissues were de-paraffinized, rehydrated, antigen retrieved, and incubated with rabbit anti-N-Myc (1:1,000) antibody overnight. The tissue sections were then incubated with biotinylated anti-rabbit (1:500) antibody, streptavidin peroxidase and diaminobenzidine.
Slides were scanned, images taken, and positively stained cells quantified using ImageJ software (National Institutes of Health) (18) .
Statistical analysis
All experiments were replicated at least three times for statistical analysis. Differences were tested for significance using ANOVA among groups or unpaired t-test for two groups.
All statistical tests were two-sided. Synergy or additivity was calculated by combination index (CI) method for combinations of multiple doses of drugs (20) , or by the fractional product (R) method for combinations of a single dose of two drugs (21, 22) . Synergism is defined as a more than additive effect (CI < 1 or R < 1).
Results
The BET bromodomain proteins BRD3 and BRD4 induce N-Myc expression and neuroblastoma cell proliferation, but do not function synergistically
The BET bromodomain protein BRD4 has been shown to modulate MYC and MYCN gene transcription (3, 4, 7, 8, 13) . We examined whether BRD3 also regulated MYCN gene expression, and whether BRD3 and BRD4 co-operatively modulated MYCN gene expression. (Fig. 2C, Fig. 2D and Supplementary Fig.   S4 ). The data confirm that JQ1 and panobinostat synergistically induce apoptosis in neuroblastoma but not normal cells.
JQ1 and panobinostat synergistically modulate target gene expression
As BET bromodomain inhibitors and HDAC inhibitors exert anticancer effects by modulating gene expression, genome-wide differential gene expression studies were performed with Affymetrix microarray in SK-N-BE(2) cells 6 hours after treatment with control solvent, 1 µM JQ1, 10 nM panobinostat, or the combination of JQ1 and panobinostat.
Using 2-fold change as the cut-off, analysis of the microarray data with GenePattern software showed that JQ1 up-regulated the expression of 14.5% (51/352) genes activated by panobinostat, and panobinostat up-regulated the expression of 29.8% (51/171) genes activated by JQ1 (Fig. 3A) . Similarly, JQ1 down-regulated the expression of 27.5% (192/511) genes suppressed by panobinostat, and panobinostat down-regulated the expression of 54.9% (192/350) genes suppressed by JQ1 (Fig. 3A) . The data suggest that JQ1 and panobinostat commonly activate, and more considerably commonly repress, target gene expression in neuroblastoma cells.
Importantly, the microarray data showed that the JQ1 and panobinostat combination synergistically modulated target gene expression (Fig. 3A) . For example, using the fold change cut-off of 4-fold, LimmaGP analysis showed that JQ1 alone and panobinostat alone regulated the expression of 10 and 20 target genes respectively, and JQ1 and panobinostat combination modulated the expression of 109 genes (Fig. 3A) . In addition, GSEA analysis revealed significant enrichment of MYC/MYCN amplification and HDAC target gene sets as targets of JQ1 and panobinostat combination treatment (Fig. 3B and Supplementary Table   S2 ).
Among the genes most significantly down-regulated by the JQ1 and panobinostat combination were the LIN28B and BCL2 oncogenes (Fig. 3C and Supplementary Table S3) .
RT-PCR analysis confirmed that JQ1 and panobinostat synergistically reduced LIN28B and BCL2 mRNA expression in SK-N-BE(2) cells 6 hours after treatment (R < 1.0 in both cases, fractional product method) (Fig. 3D) . Taken together, the data suggest that JQ1 and panobinostat synergistically modulate target gene expression. 
of LIN28B protein, 36 and 48 hours post-treatment (Fig. 4B) . In comparison, N-Myc mRNA expression was reduced by JQ1, and the JQ1/panobinostat combination did not synergize in reducing N-Myc mRNA expression (Fig. 4A) . Importantly, combination treatment with JQ1 and panobinostat synergistically and significantly reduced N-Myc protein expression in both of the cell lines at 36 and 48 hours post-treatment (Fig. 4B ).
GSK3β protein phosphorylation and Aurora A protein over-expression are wellknown to promote and block N-Myc protein degradation respectively (2). We therefore examined whether JQ1 and panobinostat co-operatively increased GSK3β protein phosphorylation and reduced Aurora A protein expression. As shown in Supplementary Fig.   S5A , combination therapy with JQ1 and panobinostat synergistically reduced N-Myc protein expression but did not show consistent effects on GSK3β protein phosphorylation and Aurora A protein expression. We then transfected SK-N-BE(2) and Kelly cells with control siRNA, LIN28B siRNA-1 or LIN28B siRNA-2. RT-PCR and immunoblot analyses showed that knocking down LIN28B did not affect N-Myc mRNA expression (Fig. 4C ), but significantly down-regulated N-Myc protein expression (Fig. 4D) . In addition, immuoblot analysis showed that transfection with LIN28B siRNAs did not have an effect on Aurora A protein expression in SK-N-BE(2) and Kelly cells (Supplementary Fig. S5B ).
We next examined whether JQ1 and panobinostat co-operatively regulated LIN28B
and N-Myc protein expression in other neuroblastoma cell lines. Immunoblot analysis confirmed that JQ1 and panobinostat synergistically reduced the expression of both LIN28B
and N-Myc proteins in CHP134 and LAN1 neuroblastoma cells (Fig. 4E) . Taken together, the data suggest that JQ1 and panobinostat synergistically reduce N-Myc protein expression by suppressing LIN28B gene expression.
BRD3 and BRD4 up-regulate LIN28B gene expression through direct binding to the

LIN28B gene promoter
As the BET bromodomain inhibitor JQ1 significantly down-regulates LIN28B mRNA and protein expression (Fig. 4A and Fig. 4B ), we investigated whether the BET bromodomain proteins, BRD3 and BRD4, modulate LIN28B expression. SK-N-BE(2) and Kelly neuroblastoma cells were transfected with control siRNA, BRD3 siRNA-1, BRD3 siRNA-2, BRD4 siRNA-1 or BRD4 siRNA-2. RT-PCR and immunoblot analyses showed that BRD3 siRNAs and BRD4 siRNAs reduced LIN28B mRNA and protein expression ( Fig.   5A and Fig. 5B ).
To determine whether LIN28B is a direct BRD3 and BRD4 target gene, ChIP assays were performed to assess whether BRD3 or BRD4 associate with the LIN28B gene promoter using PCR primers targeting a negative control and the intron 1 regions of the LIN28B gene (Fig. 5C) , as described by Chang and colleagues (15) . ChIP assays showed that immunoprecipitation with the anti-BRD3 and the anti-BRD4 antibodies significantly enriched the intron 1 region of the LIN28B gene, compared with the negative control region (Fig. 5D) . Importantly, enrichment of the LIN28B gene promoter (intron 1) by the anti-BRD3 and the anti-BRD4 antibodies was dramatically reduced after the cells were treated with JQ1 (Fig. 5D ).
To demonstrate activation of the LIN28B gene promoter by BRD3 or BRD4, we employed the pGL3 luciferase reporter construct containing empty vector or the LIN28B gene promoter (-1414 to +1403bp) (15) . Kelly cells were transfected with control siRNA, BRD3 siRNA-1 or BRD4 siRNA-2, followed by co-transfection with Cypridina TK control construct plus the pGL3-empty vector construct or the pGL3-LIN28B promoter construct. In separate experiments, Kelly cells were co-transfected with Cypridina TK control construct plus the pGL3-empty vector construct or the pGL3-LIN28B promoter construct for 24 hours, followed by treatment with control solvent, 1 µM JQ1, 10 nM panobinostat, or combination of 1 µM JQ1 and 10 nM panobinostat for another 6 hours. Luciferase assays showed that knocking down BRD3 or BRD4 expression with siRNA significantly reduced luciferase activity of the LIN28B promoter construct (Fig. 5E) ; that treatment with JQ1 alone, but not panobinostat alone, significantly reduced luciferase activity of the LIN28B promoter construct; and that combination therapy with JQ1 and panobinostat synergistically reduced luciferase activity of the LIN28B promoter construct (Fig. 5F ). Taken together, the data suggest that BRD3 and BRD4 up-regulate LIN28B gene expression by binding to its gene promoter and activating its transcription, and that JQ1 and panobinostat synergistically reduce LIN28B gene expression by reducing its promoter activity.
JQ1 and panobinostat synergistically reduce N-Myc protein expression and block tumor progression in neuroblastoma-bearing mice
In order to evaluate the potential clinical application of JQ1 and panobinostat combination therapy, it is essential to investigate the effect of the combination therapy on neuroblastoma progression in vivo. 
Discussion
The BET bromodomain protein BRD4 has been extensively shown to modulate MYC and MYCN gene transcription in leukemia, lymphoma, myeloma and neuroblastoma cells (3, 4, 7, 8, 13) . While BRD3 has also been shown to regulate MYC gene transcription (8) 
neuroblastoma progression. Our study therefore suggests that when neuroblastoma patients are treated with BET bromodomain inhibitors in the future, they may be co-treated with the HDAC inhibitor panobinostat. The finding is consistent with recent reports that the BET bromodomain inhibitor RVX2135 and the HDAC inhibitor vorinostat synergistically kill Myc-induced murine lymphoma cells (12), and that JQ1 and panobinostat synergistically induce leukemia cell apoptosis (6).
BET bromodomain inhibitors exert biological effects by dislodging the acetylated histone readers BRD3 and BRD4 from chromatin, leading to transcriptional repression of oncogenes (7, 13, 16) . In comparison, HDAC inhibitors exert biological effects by blocking the function of HDACs, leading to transcriptional activation of tumor suppressor genes (11) .
Surprisingly, a recent study showed that treatment with RVX2135, vorinostat or panobinostat for 24 hours commonly up-regulated the expression of a subset of genes, but did not commonly down-regulate target gene expression (12). In the current study, we have found (4, 13, 17) . In this study, we have found that knocking-down BRD3 or BRD4 expression reduces LIN28B mRNA and protein expression. ChIP assays demonstrate that BRD3 and BRD4 bind to the LIN28B gene promoter, and luciferase assays show that knocking-down BRD3 or BRD4 reduces LIN28B gene promoter activity, and that JQ1 and panobinostat synergistically reduce LIN28B gene promoter activity. We therefore conclude that BRD3 and BRD4 induce LIN28B gene expression by direct binding to its gene promoter, and that JQ1 and panobinostat synergistically reduce LIN28B gene expression by blocking its promoter activity. 
